Cardiac related death in thalassaemia major: Time trend and risk factors in a large Greek Unit

European Journal of Haematology

Volumn 82, Issue 5, 2009, Pages 381-387

  Chouliaras, Giorgos ^a   Yiannoutsos, Constantin T ^b   Berdoukas, Vasilios ^a   Ladis, Vassilios ^a  

^a AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Cardiac death; Haemosiderosis; Survival; Thalassaemia; Time trend

Indexed keywords

FERRITIN;

ADULT; ARTICLE; DISEASE SEVERITY; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GREECE; HEART DEATH; HEMOSIDEROSIS; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SURVIVAL; THALASSEMIA MAJOR; TREND STUDY;

AGE FACTORS; BETA-THALASSEMIA; DEATH; FEMALE; GREECE; HEART DISEASES; HEMOSIDEROSIS; HUMANS; MALE; RISK FACTORS; SEX FACTORS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 64249113129     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01218.x     Document Type: Article

References (21)

1. Rund D, Rachmilewitz E. New trends in the treatment of beta-thalassemia. Crit Rev Oncol Hematol 2000 33 : 105 18.
2. Ladis V, Berdousi H, Palamidou F, et al. Morbidity and mortality of iron intoxication in adult patients with thalassemia major, and effectiveness of chelation. Transfus Sci 2000 23 : 255 6.
3. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004 89 : 1187 93.
4. Ladis V, Chouliaras G, Berdousi H, Kanavakis E, Kattamis C. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. Ann N Y Acad Sci 2005 1054 : 445 50.
5. Telfer P, Coen PG, Christou S, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica 2006 91 : 1187 92.
6. Berdoukas V, Modell B. Transfusion-dependent thalassaemia: a new era. Med J Aust 2008 188 : 68 9.
7. Kattamis A, Dinopoulos A, Ladis V, Berdousi H, Kattamis C. Variations of ferritin levels over a period of 15 years as a compliance chelation index in thalassemic patients. Am J Hematol 2001 68 : 221 4.
8. Kattamis C. Optimal use of desferrioxamine in the treatment of thalassaemia. 2nd International Conference on Thalassemia and the Hemoglobinopathies. Herakleion, Crete : Hans Huber, 1997 : 11 25.
9. Clayton D, Hills M. Statistical Models in Epidemiology. Oxford : Oxford Science Publications, 1993.
10. Collett D. Modelling Survival Data in Medical Research, 2nd edn. London : Chapman & Hall, 2003.
11. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000 355 : 2051 2.
12. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2008 10 : 42.
13. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006 107 : 3733 7.
14. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003 88 : 489 96.
15. Tavecchia L, Masera N, Russo P, et al. Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone. Haematologica 2006 91 : ECR19.
16. Tsironi M, Deftereos S, Andriopoulos P, Farmakis D, Meletis J, Aessopos A. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. Eur J Haematol 2005 74 : 84 5.
17. Wu KH, Chang JS, Tsai CH, Peng CT. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. Ann Hematol 2004 83 : 471 3.
18. Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 2008 10 : 12.
19. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000 95 : 1229 36.
20. Miskin H, Yaniv I, Berant M, Hershko C, Tamary H. Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. Eur J Haematol 2003 70 : 398 403.
21. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of beta-thalassemia major in North America. Blood 2004 104 : 34 9.